Home / Executive Moves / A&D Tech Industry Vets Carl Johnson, Rebecca McGrane Join Norsk Titanium

A&D Tech Industry Vets Carl Johnson, Rebecca McGrane Join Norsk Titanium

Norsk Titanium logoAviation component manufacturer Norsk Titanium has named Carl Johnson as senior vice president of technology, engineering and quality and Rebecca McGrane as vice president and general manager of its technology center.

Norsk Titanium said Monday Johnson, a veteran of Northrop Grumman (NYSE: NOC) for more than three decades; and McGrane,  who spent 15 years at General Dynamics (NYSE: GD); will work to help the Norway-based titanium additive producer supply its Rapid Plasma Deposition-based machine parts to defense and aerospace companies.

Johnson previously served as a vice president and program manager at Northrop, where he worked on the development of the X-47B unmanned aircraft system for the U.S. Navy and the Global Hawk UAS for the U.S. Air Force.

He is a two-time recipient of the Robert J. Collier Trophy for his work on the two UAS programs.

McGrane has held senior leadership roles during her 15-year career at General Dynamics’ land systems business, including director of the maneuver collaboration center, manager of Stryker systems engineering and director of wheeled combat and tactical vehicles.

She has received awards in recognition of her work in the field of engineering, materials science and composites such as the Horizon Industry Award for Technical Achievement and the Certificate of Commendation from the U.S. Marine Corps.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.